Satellos Bioscience Inc. Common Stock - Asset Resilience Ratio
Satellos Bioscience Inc. Common Stock (MSLE) has an Asset Resilience Ratio of 56.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Satellos Bioscience Inc. Common Stock's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Satellos Bioscience Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Satellos Bioscience Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MSLE company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.91 Million | 56.15% |
| Total Liquid Assets | $17.91 Million | 56.15% |
Asset Resilience Insights
- Very High Liquidity: Satellos Bioscience Inc. Common Stock maintains exceptional liquid asset reserves at 56.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Satellos Bioscience Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Satellos Bioscience Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Satellos Bioscience Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Satellos Bioscience Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.15% | $17.91 Million | $31.89 Million | +39.45pp |
| 2024-12-31 | 16.70% | $8.50 Million | $50.88 Million | -22.85pp |
| 2023-12-31 | 39.55% | $13.21 Million | $33.39 Million | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more